MARIPOSA-2 Phase 3 Study Design and Treatment Arms

Opinion
Video

This segment discusses the details of the phase 3 randomized MARIPOSA-2 trial design evaluating amivantamab plus chemotherapy vs amivantamab, lazertinib and chemotherapy vs chemotherapy alone in osimertinib-resistant EGFR-mutant NSCLC.

Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Related Content